Fetuin-A (AHSG) Human ELISA
Fetuin-A (AHSG), a 59 kDa glycoprotein, consists of two cystatin-like domains and a smaller unrelated domain. Its homologues have been identified in several species including rat (pp63), mouse, guinea pig, rabbit, sheep, cattle, swine and human. AHSG human gene is located on chromosome 3q27.
Liver synthesized fetuin-A is secreted into the blood stream and it is deposited as a noncollagenous protein in mineralized bones and teeth. Fetuin-A occurs in high serum concentration during fetal life, whereas its level declines following infection, inflammation (by 20-30% during acute phase) and malignancy. Fetuin-A may influence the resolution of inflammation by modulating the phagocytosis of apoptotic cells by macrophages.
Fetuin-A acts as an important circulating inhibitor of ectopic calcification that is a frequent complication of many degenerative diseases. The low fetuin-A level may be associated with higher cardiovascular mortality in chronic renal failure, liver cancer and liver cirrhosis patients on long-term dialysis. Human fetuin-A represents a natural inhibitor of tyrosine kinase activity of the insulin receptor.
Fetuin-A may play a significant role in regulating postprandial glucose disposal, insulin sensitivity, weight gain, and fat accumulation and may be a novel therapeutic target in the treatment of type 2 diabetes, obesity, and other insulin-resistant conditions. The serum and bone-resident fetuin-A binds to transforming growth factor-β and blocks TGF-β binding to cell surface receptors. Thus, fetuin-A is involved at least in inhibition of unwanted (vascular) calcification, inhibition of insulin receptor tyrosine kinase activity and regulation of osteogenesis.
Type
Sandwich ELISA, HRP-labelled antibody
Applications
Serum, Plasma-EDTA, Plasma-Heparin, Plasma-Citrate, Cell culture medium, Urine, Cerebrospinal fluid
Sample Requirements
10 µl/well
Storage/Expiration
Store the kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).
Calibration Curve
Calibration Range
2–100 ng/ml
Limit of Detection
0.104 ng/ml
Intra-assay (Within-Run)
n = 8; CV = 2.9%
Inter-assay (Run-to-Run)
n = 6; CV = 4.7%
Spiking Recovery
108,80%
Dilutation Linearity
110,40%
Crossreactivity
bovine Non-detectable
cat Non-detectable
dog Non-detectable
goat Non-detectable
hamster Non-detectable
horse Non-detectable
mouse Non-detectable
pig Non-detectable
rabbit Non-detectable
rat Non-detectable
sheep Non-detectable
chicken Not tested
human Yes
monkey Yes (recommended dilution 1:5000)
– Abali R, Celik C, Tasdemir N, Guzel S, Alpsoy S, Yuksel A, Celik E. The serum protein alpha2-Heremans-Schmid glycoprotein/fetuin-a concentration and carotid intima-media thickness in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Bi. 2013 Jul;169 (1):45-9
– Aleksandrova K, Giuseppe RD, Isermann B, Biemann R, Schulze MB, Wittenbecher C, Fritsche A, Lehmann R, Menzel J, Weikert C, Pischon T, Boeing H. Circulating Omentin as a Novel Biomarker for Colorectal Cancer Risk: Data from the EPIC – Potsdam Cohort Study. Cancer Res. 2016 May 23;
– Argani H, Ghorbanihaghjo A, Panahi G, Rashtchizadeh N, Safa J, Meimand SM. Serum Fetuin-A and Pentraxin3 in hemodialysis and renal transplant patients. Clin Biochem. 2012 Jul;45 (10-11):775-9
– Bakiner O, Bozkirli E, Ertugrul D, Sezgin N, Ertorer E. Plasma fetuin-A levels are reduced in patients with hypothyroidism. Eur J Endocrinol. 2014 Mar;170 (3):411-8
– Blaha V, Mistrik E, Dusilova-Sulkova S, Kalousova M, Andrys C, Blaha M, Sobotka L. Circulating fetuin-A predicts early mortality in chronic hemodialysis patients. Clin Biochem. 2009 Jul;42 (10-11):996-1000
– Brettschneider J, Lehmensiek V, Mogel H, Pfeifle M, Dorst J, Hendrich C, Ludolph AC, Tumani H. Proteome analysis reveals candidate markers of disease progression in amyotrophic lateral sclerosis (ALS). Neurosci Lett. 2010 Jan 1;468 (1):23-7
– Briana DD, Boutsikou M, Gourgiotis D, Boutsikou T, Baka S, Marmarinos A, Hassiakos D, Malamitsi-Puchner A. Serum fetuin-A/alpha2-HS-glycoprotein in human pregnancies with normal and restricted fetal growth. J Matern Fetal Neonatal Med. 2008 Nov;21 (11):826-30
– Brix JM, Stingl H, Hollerl F, Schernthaner GH, Kopp HP, Schernthaner G. Elevated Fetuin-A concentrations in morbid obesity decrease after dramatic weight loss. J Clin Endocrinol Metab. 2010 Nov;95 (11):4877-81
– Caglar K, Yilmaz MI, Saglam M, Cakir E, Acikel C, Eyileten T, Yenicesu M, Oguz Y, Vural A, Carrero JJ, Axelsson J, Lindholm B, Stenvinkel P. Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol. 2008 Jan;3 (1):61-8
– Caglar K, Yilmaz MI, Saglam M, Cakir E, Kilic S, Sonmez A, Eyileten T, Yenicesu M, Oguz Y, Tasar M, Vural A, Ikizler TA, Stenvinkel P, Lindholm B. Serum fetuin-a concentration and endothelial dysfunction in chronic kidney disease. Nephron Clin Pract. 2008;108 (3):c233-40
– Cagli K, Basar N, Cagli K, Armutcu F, Aylak F, Yalcinkaya A, Erden G, Kadirogullari E. Association of serum fetuin-A with valvular calcium concentration in rheumatic mitral valve disease. J Heart Valve Dis. 2010 Sep;19 (5):636-43
– Chang WT, Wu CH, Hsu LW, Chen PW, Yu JR, Chang CS, Tsai WC, Liu PY. Serum vitamin D, intact parathyroid hormone, and Fetuin A concentrations were associated with geriatric sarcopenia and cardiac hypertrophy. Sci Rep. 2017 Jan 23;7:40996. doi: 10.1038/srep40996
– Cianciolo G, La Manna G, Donati G, Persici E, Dormi A, Cappuccilli ML, Corsini S, Fattori R, Russo V, Nastasi V, Coli L, Wratten M, Stefoni S. Coronary calcifications in end-stage renal disease patients: a new link between osteoprotegerin, diabetes and body mass index?. Blood Purif. 2010;29 (1):13-22
– Cutler P, Akuffo EL, Bodnar WM, Briggs DM, Davis JB, Debouck CM, Fox SM, Gibson RA, Gormley DA, Holbrook JD, Hunter AJ, Kinsey EE, Prinjha R, Richardson JC, Roses AD, Smith MA, Tsokanas N, Willé DR, Wu W, Yates JW, Gloger IS. Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: Two novel biomarkers of Alzheimer’s disease in human plasma. Proteomics. 7 Mar 2008;2 Issue 4:467 – 477
– Dalamaga M, Karmaniolas K, Chamberland J, Nikolaidou A, Lekka A, Dionyssiou-Asteriou A, Mantzoros CS. Higher fetuin-A, lower adiponectin and free leptin levels mediate effects of excess body weight on insulin resistance and risk for myelodysplastic syndrome. Metabolism. 2013 Dec;62 (12):1830-9
– Dervisoglu E, Kir HM, Kalender B, Caglayan C, Eraldemir C. Serum fetuin–a concentrations are inversely related to cytokine concentrations in patients with chronic renal failure. Cytokine. 2008 Dec;44 (3):323-7
– Eller P, Hochegger K, Feuchtner GM, Zitt E, Tancevski I, Ritsch A, Kronenberg F, Rosenkranz AR, Patsch JR, Mayer G. Impact of ENPP1 genotype on arterial calcification in patients with end-stage renal failure. Nephrol Dial Transplant. 2008 Jan;23 (1):321-7
– Emoto M, Mori K, Lee E, Kawano N, Yamazaki Y, Tsuchikura S, Morioka T, Koyama H, Shoji T, Inaba M, Nishizawa Y. Fetuin-A and atherosclerotic calcified plaque in patients with type 2 diabetes mellitus. Metabolism. 2010 Jun;59 (6):873-8
– Eraso LH, Ginwala N, Qasim AN, Mehta NN, Dlugash R, Kapoor S, Schwartz S, Schutta M, Iqbal N, Mohler ER 3rd, Reilly MP. Association of lower plasma fetuin-a levels with peripheral arterial disease in type 2 diabetes. Diabetes Care. 2010 Feb;33 (2):408-10
– Ford ML, Tomlinson LA, Smith ER, Rajkumar C, Holt SG. Fetuin-A is an independent determinant of change of aortic stiffness over 1 year in non-diabetic patients with CKD stages 3 and 4. Nephrol Dial Transplant. 2010 Jan 14;
– Hamano T, Matsui I, Mikami S, Tomida K, Fujii N, Imai E, Rakugi H, Isaka Y. Fetuin-mineral complex reflects extraosseous calcification stress in CKD. J Am Soc Nephrol. 2010 Nov;21 (11):1998-2007
– Harris VK, Donelan N, Yan QJ, Clark K, Touray A, Rammal M, Sadiq SA. Cerebrospinal fluid fetuin-A is a biomarker of active multiple sclerosis. Mult Scler. 2013 Oct;19 (11):1462-72
– Hennige AM, Staiger H, Wicke C, Machicao F, Fritsche A, Haring HU, Stefan N. Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One. 2008;3 (3):e1765
– Hussein NA, Mahmoud OM, Zahran MY, Rafaat MA. Serum Fetuin-A in Chronic Renal Disease Patients: Contribution to Endothelial Dysfunction and Hemostatic alteration. Journal of American Science. 2010;6(12);
– Hwang JJ, Thakkar B, Chamberland JP, Mantzoros CS. Circulating fetuin-A levels are not affected by short and long-term energy deprivation and/or by leptin administration. Metabolism. 2014 Feb 17;
– Ishibashi A, Ikeda Y, Ohguro T, Kumon Y, Yamanaka S, Takata H, Inoue M, Suehiro T, Terada Y. Serum fetuin-A is an independent marker of insulin resistance in Japanese men. J Atheroscler Thromb. 2010 Sep 30;17 (9):925-33
– Jimenez MC, Sun Q, Schurks M, Hu FB, Manson JE, Rexrode KM. Circulating fetuin-a and risk of ischemic stroke in women. Clin Chem. 2014 Jan;60 (1):165-73
– Kaden JJ, Reinohl JO, Blesch B, Brueckmann M, Haghi D, Borggrefe M, Schmitz F, Klomfass S, Pillich M, Ortlepp JR. Systemic and local levels of fetuin-A in calcific aortic valve stenosis. Int J Mol Med. 2007 Aug;20 (2):193-7
– Kaess BM, Enserro DM, McManus DD, Xanthakis V, Chen MH, Sullivan LM, Ingram C, O’Donnell CJ, Keaney JF, Vasan RS, Glazer NL. Cardiometabolic correlates and heritability of fetuin-a, retinol-binding protein 4, and Fatty-Acid binding protein 4 in the framingham heart study. J Clin Endocrinol Metab. 2012 Oct;97 (10):E1943-7
– Kamel AA, El-Attar HA, Abaza MM, Gaber EW, Badawi SS. Study of serum osteoprotegerin (OPG), tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and fetuin-A in patients with chronic renal failure. Bull. Alex. Fac. Med. 2007;43 (3)
– Kanbay M, Nicoleta M, Selcoki Y, Ikizek M, Aydin M, Eryonucu B, Duranay M, Akcay A, Armutcu F, Covic A. Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. Clin J Am Soc Nephrol. 2010 Oct;5 (10):1780-6
– Katayama H, Paczesny S, Prentice R, Aragaki A, Faca VM, Pitteri SJ, Zhang Q, Wang H, Silva M, Kennedy J, Rossouw J, Jackson R, Hsia J, Chlebowski R, Manson J, Hanash S. Application of serum proteomics to the Women’s Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings. Genome Med. 2009;1 (4):47 – Kaushik SV, Plaisance EP, Kim T, Huang EY, Mahurin AJ, Grandjean PW, Mathews ST. Extended-release niacin decreases serum fetuin-A concentrations in individuals with metabolic syndrome. Diabetes Metab Res Rev. 20